

NIEUWSBRIEF KLINISCHE STUDIES THORAXONCOLOGIE

NOVEMBER 2024

www.uza.be/studies-oncologie#thorax



NIEUWE STUDIES IN DE KIJKER

WU-KONG28 (Dizal): A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

NSCLC 1L – EGFR exon 20 insertion

Recent geopend

KRASCENDO-1 (Roche): A Phase III, Randomized, Open-Label, Multicenter Study Evaluating The Efficacy And Safety Of Divarasib Versus Sotorasib Or Adagrasib In Patients With Previously Treated KRAS G12C-Positive Advanced Or Metastatic Non-Small Cell Lung Cancer

NSCLC 2-4L – KRAS G12C

Opent binnenkort

NIET-KLEINCELLIG LONGCARCINOOM

JZJX (Eli Lilly): A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432)

adjuvant NSCLC – RET-fusie

PACIFIC-8 (AstraZeneca): A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab in Participants with Locally Advanced (Stage III), Unresectable NSCLC Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy

stadium III NSCLC – na concurrente chemoradiotherapie

LUNG Platform (GSK): A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, PD-L1-Selected NSCLC

NSCLC 1L – PD-L1 \geq 50%

Voor meer informatie contacteer [Giete Moons](#) | [Jolien Op de Beeck](#)

Stafleden thoraxoncologie: [Annelies Janssens](#) | [Jo Raskin](#) | [Reinier Wener](#) | [Mick van de Wiel](#)

Fase I studies: [Bernd Dekeyser](#)

KRYSTAL-7 (Mirati Therapeutics): A Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation.

NSCLC 1L - KRAS G12C + PD-L1 \geq 50%

SAFFRON (AstraZeneca): A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Vs Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic NSCLC Who Have Progressed on Treatment With Osimertinib

NSCLC - EGFRm+ na osimertinib

TeliMET NSCLC-01 (AbbVie): A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous NSCLC

NSCLC 2L - non-squamous cMET overexp - nog geen docetaxel gehad

Be6A Lung-01 (Seagen): A Randomized, Phase 3, Open-label Study to Evaluate SGN-B6A (Sigvodatug Vedotin) Compared to Docetaxel in Adult Subjects with Previously Treated Non-Small Cell Lung Cancer.

*NSCLC 2L - non-squamous - nog geen docetaxel gehad
actionable molecular alteration toegelaten*

WU-KONG28 (Dizal): A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

NSCLC 1L - EGFR exon 20 insertion

DO2.22.01 (Deuter Oncology): A Phase 1 Study to Determine the Safety, and Pharmacokinetics of the Selective MET kinase Inhibitor, DO-2 in Patients With Advanced or Refractory Solid Tumours

NSCLC post SOC - METamp/METex14skipping

TRIDENT-1 (Turning Point Therapeutics): A Phase 1/2, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 (repotrectinib) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

NSCLC - NTRK+ (ALK+ en ROS1+ niet meer open)

Voor meer informatie contacteer [Giete Moons](#) | [Jolien Op de Beeck](#)

Stafleden thoraxoncologie: [Annelies Janssens](#) | [Jo Raskin](#) | [Reinier Wener](#) | [Mick van de Wiel](#)

Fase I studies: [Bernd Dekeyser](#)

TAPISTRY (Roche): Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You Platform Study

NSCLC post SOC - NTRK+

21820 (Bayer): First-in-human dose-escalation and expansion study to evaluate the safety, tolerability, and pharmacokinetics of the anti-CCR8 antibody BAY 3375968 as monotherapy and in combination with pembrolizumab in participants with selected advanced solid tumors

NSCLC post SOC

Momenteel geen sloten

20210023 (AMGEN): AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

NSCLC post SOC - MTAP-verlies

IMC-F106C-101 (Immunocore): A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers

*NSCLC post SOC - HLA-A*02:01-positief en PRAME-positief*

20210104 (AMGEN): A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression

NSCLC adeno 2L - FGFR2b overexp

Brightline-2 (Boehringer): A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 for treatment of patients with locally advanced/metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumours

NSCLC adeno post SOC

Voor meer informatie contacteer [Giete Moons](#) | [Jolien Op de Beeck](#)

Stafleden thoraxoncologie: [Annelies Janssens](#) | [Jo Raskin](#) | [Reinier Wener](#) | [Mick van de Wiel](#)

Fase I studies: [Bernd Dekeyser](#)

JK07.1.01 (Salubris Bio): A Phase 1/2, Multicenter, Open Label, Dose Escalation & Dose Expansion Study of JK08, an IL-15 Antibody Fusion Protein Targeting CTLA-4, in Patients with Unresectable Locally Advanced or Metastatic Cancer

NSCLC max 3L

Momenteel geen sloten

21948 (Bayer): An open-label, phase 1, first-in-human, dose escalation and expansion study to evaluate the safety, tolerability, maximum tolerated or administered dose, pharmacokinetics, pharmacodynamics, and tumor response profile of the diacylglycerol kinase zeta inhibitor (DGKzi) BAY 2965501 as monotherapy, and in combination, in participants with advanced solid tumors

NSCLC prior SOC

DAREON-7 (Boehringer): A Phase I, open-label, dose escalation and expansion trial to investigate safety and tolerability of BI 764532 intravenous infusions in combination with standard of care (platinum and etoposide) in first-line treatment of patients with neuroendocrine carcinomas

LCNEC 1L - DLL3+

KLEINCELLIG LONGCARCINOOM

PRIMALung (EORTC): PRophylactic cerebral Irradiation or active MAgnetic resonance imaging surveillance in small-cell Lung cancer patients

LD-SCLC en ED-SCLC na (immuno)chemotherapie of chemoradiotherapie

LAGOON (PharmaMar): A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed SCLC Patients

ED-SCLC 2L - rechallenge met eerste lijn niet toegelaten

Voor meer informatie contacteer [Giete Moons](#) | [Jolien Op de Beeck](#)

Stafleden thoraxoncologie: [Annelies Janssens](#) | [Jo Raskin](#) | [Reinier Wener](#) | [Mick van de Wiel](#)

Fase I studies: [Bernd Dekeyser](#)

PLEURAAL MESOTHELIOOM

HiPeRMESO (Academisch): High-intensity Pleural Radiotherapy after (extended) pleurectomy and decortication in patient with pleural MESOthelioma

adjuvant mesotheliom 1L

SOLIDE TUMOREN - PSYCHOSOCIAAL

REMOTE (Academisch) Targeting Fear of Cancer Recurrence in Cancer Survivors: a multicentre randomized controlled trial to evaluate Internet-Based Emotional Freedom Techniques and Internet-Based Mindfulness Meditation as intervention strategies

Kankerpatiënten in remissie met angst voor herval

EPITHELIALE TUMOREN VAN DE THYMUS

Geen beschikbare studies

Voor meer informatie contacteer [Giete Moons](#) | [Jolien Op de Beeck](#)

Stafleden thoraxoncologie: [Annelies Janssens](#) | [Jo Raskin](#) | [Reinier Wener](#) | [Mick van de Wiel](#)

Fase I studies: [Bernd Dekeyser](#)